Isoleucine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Isoleucine: From No Approved Indication to Gastroparesis
One-Sentence Summary
Isoleucine is an essential branched-chain amino acid (BCAA) with no approved therapeutic indication and no marketed product in New Zealand. The TxGNN model predicts it may be effective for Gastroparesis, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no approved therapeutic indication on record |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 99.32% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for isoleucine in this evidence pack. As a naturally occurring essential BCAA, it has no formal drug indication on record and is not marketed in New Zealand, so there is no established original indication to anchor a mechanistic comparison against.
The repurposing hypothesis is purely physiological reasoning: isoleucine, as a BCAA, could theoretically influence gastric emptying and gut motility through vagal afferent signaling, insulin/mTOR pathway activity, or incretin modulation. This is a plausible biological pathway, but it has not been demonstrated in any preclinical, clinical, or published literature source — the connection to gastroparesis is inferred, not evidenced.
Given the absence of MOA data, an established original indication, and any supporting studies, the mechanistic rationale should be treated as speculative rather than substantiated.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Isoleucine is not marketed in New Zealand and holds no product authorizations (0 licenses on record). No approved indication text is available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5, no clinical trials or literature), the drug's mechanism of action is undocumented, and it is not currently marketed in New Zealand — there is insufficient evidence to advance this candidate.
To proceed, the following is needed:
- TFDA/Medsafe package insert (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action data from DrugBank or primary literature
- Preclinical or clinical evidence linking isoleucine (or BCAA supplementation) to gastric motility/gastroparesis outcomes
- Clarification of any existing approved use (nutritional/metabolic) to establish a genuine baseline indication for comparison
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.